DadFinStart your free week
DadFin › Stocks › Healthcare › BDSX

Biodesix, Inc. (BDSX) stock score

Healthcare · Diagnostics & Research · United States

$26.02 ▲ +1.52% today

62.7
Dad Score, out of 100
middling

Biodesix, Inc. (BDSX) is a Diagnostics & Research company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 62.7 out of 100 on the Dad Score, a middling reading that places the business ahead of 63% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #320 of 974. Its strongest axes are quality, growth and risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Above average
Growth
Above average
Price action
Average
Risk
Above average
Conviction
Strong
Liquidity
Average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-126.0×
Dividend yield0.00%
Return on capital-39.3%
Operating margin-20.0%
Revenue growth (YoY)+24.1%
FCF yield-7.4%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change+267.6%
Market cap$292M
Next earningsNov 3, 2026

What subscribers see on BDSX

Start your free weekSubscriber? Open the full research →

Diagnostics & Research peers

StockCompanyDad ScoreBandMarket cap
TMOThermo Fisher Scientific Inc.77.0good$242.1B
DHRDanaher Corporation79.6good$150.5B
NTRANatera, Inc.86.1strong$59.1B
AAgilent Technologies, Inc.79.9good$47.3B
IQVIQVIA Holdings Inc.82.3good$42.5B
WATWaters Corporation78.8good$41.7B
ILMNIllumina, Inc.35.1weak$41.2B
IDXXIDEXX Laboratories, Inc.90.1strong$40.9B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.